Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - sunitinib malate 66,83 mg - eq. sunitinib 50 mg - capsule, hard - 50 mg - sunitinib malate 66.83 mg - sunitinib

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - hard capsule - sunitinib 12.5 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - hard capsule - sunitinib 25 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - hard capsule - sunitinib 37.5 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - hard capsule - sunitinib 50 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: propylene glycol; iron oxide black; isopropyl alcohol; butan-1-ol; ammonia; ethanol absolute; titanium dioxide; povidone; purified water; potassium hydroxide; mannitol; shellac; croscarmellose sodium; iron oxide yellow; magnesium stearate; sodium lauryl sulfate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 16.7 mg (equivalent: sunitinib, qty 12.5 mg) - capsule - excipient ingredients: sodium hydroxide; propylene glycol; shellac; sodium lauryl sulfate; iron oxide red; mannitol; magnesium stearate; titanium dioxide; povidone; gelatin; croscarmellose sodium - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Israel - English - Ministry of Health

teva israel ltd - sunitinib as base - capsules - sunitinib as base 12.5 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.